Abbott Laboratories (ABT) Invested Capital (2009 - 2026)

Abbott Laboratories has disclosed Invested Capital across 18 years of filings, most recently posting $86.1 billion for Q1 2026.

• Invested Capital for Q1 2026 came in at $86.1 billion, up 41.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.1 billion (up 41.88% YoY), and the FY2025 annual result was $65.5 billion, up 357.22% from the prior year.
• Invested Capital came in at $86.1 billion for Q1 2026 at Abbott Laboratories, up from $65.5 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $86.1 billion in Q1 2026 to a low of -$14.1 billion in Q3 2022.
• The 5-year median for Invested Capital is $15.0 billion (2024), against an average of $28.6 billion.
• Across the five-year window, Invested Capital plunged 1980.59% in 2022 and soared 1454.56% in 2023, its largest moves.
• Abbott Laboratories' Invested Capital stood at $41.5 billion in 2022, then tumbled by 64.51% to $14.7 billion in 2023, then slipped by 2.62% to $14.3 billion in 2024, then soared by 357.22% to $65.5 billion in 2025, then soared by 31.38% to $86.1 billion in 2026.
• The last three Invested Capital figures came in at $86.1 billion (Q1 2026), $65.5 billion (Q4 2025), and $64.1 billion (Q3 2025), per Business Quant data.